The importance of these recent findings is one more example that, regardless of the cause of the neurodegenerative condition (known versus unknown etiology, injury versus genetic abnormality), the therapeutic and translational potential of SynCav1 might be exploited in the future to treat sporadic neurodegenerative conditions or to be used in combination with already existing drugs or biologics designed to target known monogenic candidates linked to other neurodegenerative conditions (EOFAD, FALS, Parkinson’s, and Huntingtin’s disease). This evidence concerns the gene HTT and Parkinsonism.